Ref. No.P-66/2026-27/26
August 13, 2026

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Subject: Outcome of Board Meeting held on Thursday, 13th August, 2026

Pursuant to Regulations 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations),we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. 13th August, 2026, has inter-alia, considered and approved the following:

1. Financial results:

Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June 2026. The same has also been reviewed by the Audit Committee in its meeting held today.

Further, Baheti & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2026 and the Board has also taken on record their Limited Review Reports on the said Financial Results.

A copy of the Financial Results along with Limited Review Report for the quarter ended 30th June, 2026, as required under Regulation 33 of the Listing Regulations, is attached.

2. Appointment of M/s Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor, Bhopal as Cost Auditor of the Company for the FY 2026-27;

The said appointment of M/s. Sanjay Kasliwal & Associates is in compliance with Section 148 of the Companies Act, 2013 and other applicable provisions, if any, read with Companies (Cost Records and Audit) Rules, 2014. The remuneration payable to M/s Sanjay Kasliwal & Associates shall be placed before the shareholders for ratification at the ensuing Annual General Meeting.

The disclosure pursuant to SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure -A

The Meeting of the Board of Directors held today commenced at 3:00 P.M. and concluded at 3:50 P.M.

Kindly take the same on your records.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

NIKHILKUBER DUBEY

Digitally signed by NIKHILKUBER DUBEY
Date: 2026.08.13 15:56:03 +05'30'

Nikhil Kuber Dubey
Whole Time Director
DIN: 00538049

3B BlackBio Dx Ltd.
(Formerly - Kilpest India Limited)

ANNEXURE-A

DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated JANUARY 30, 2026

Name	M/s. Sanjay Kasliwal & Associates
Reason for change viz. appointment, ~~re-appointment resignation, removal, death or otherwise~~	Appointment
Date of appointment/ ~~re-appointment/ cessation (as applicable) & term of appointment/re-appointment~~	Appointed as Cost Auditor for FY 2026-27 at the Board meeting held on 13th August, 2026, to issue Cost Audit Report as per the provisions of the Companies Act, 2013
Brief Profile (in case of appointment);	M/s. Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor, Bhopal (Firm Regd. No. 100888) has experience and expertise in Cost Audit over the years. The firm also provides Guidance for Maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014 and certification as regards maintenance of Cost Records by the Company.
Disclosure of relationships between directors (in case of appointment of a director)	NA

For 3B BlackBio Dx Limited

Director

3B BLACKBIO DX LIMITED

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023

CIN:L24211MP1972PLC001131

Statement of Standalone Unaudited Financial Results For The Quarter Ended 30-06-2026

(Rs. In Lakhs)

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operations	2294.52	2463.01	2035.71	9727.50
II	Other income	530.27	130.33	431.42	1416.20
III	**Total Income (I + II)**	**2824.79**	**2593.34**	**2467.13**	**11143.70**
IV	**Expenses:**				
	Cost of materials consumed	493.25	578.96	519.70	2345.16
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-	(29.94)	29.80	(5.97)	11.69
	Employee benefits expenses	182.86	225.92	148.81	757.93
	Finance costs	0.02	0.41	0.80	4.39
	Depreciation and amortization expense	23.50	29.31	21.50	94.31
	Other expenses	319.78	500.15	214.35	1294.54
	Total expenses (IV)	**989.47**	**1364.55**	**899.19**	**4508.02**
V	**Profit/(loss) before exceptional items and tax (III - IV)**	**1835.32**	**1228.79**	**1567.94**	**6635.68**
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	**Profit before tax (V - VI)**	**1835.32**	**1228.79**	**1567.94**	**6635.68**
VIII	Tax expense:				
	(1) Current tax	424.11	395.64	321.90	1615.49
	(2) Deferred tax	0.00	88.50	0.00	88.50
IX	**Profit (Loss) for the period (VII-VIII)**	**1411.21**	**744.65**	**1246.04**	**4931.69**
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00
XI	**Total Comprehensive Income for the period (IX+X)**	**1411.21**	**744.65**	**1246.04**	**4931.69**
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	31044.75	26421.76	26421.76	26421.76
XIV	**Earnings per equity share:**				
	(1) Basic	16.47	8.69	14.54	57.56
	(2) Diluted	16.47	8.69	14.54	57.56

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE: BHOPAL
DATE : 13/08/2026

3B BlackBio Dx Ltd.
(Formerly - Kilpest India Limited)

NOTES ON STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on August 13, 2026 after being reviewed by the Audit Committee.
2. The Company's Agrochemical Business is seasonal in nature and the performance can be impacted by weather conditions and cropping pattern.
3. These financial results have been prepared In accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended.
4. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures for the full financial year ended March 31, 2026 and unaudited figures for the nine months ended December 31, 2025, being the date of the end of the third quarter of the financial year, which were subjected to limited review.
5. All the figures of financials have been rounded off to nearest lakh in rupees.
6. There is an increase in other expenses by 3% which is mainly because of expenditure incurred towards IVDR regulatory registration process and participation in international trade fair.
7. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
8. The results of the company are available for investors at www.kilpest.com and www.bseindia.com.

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter ended June 30, 2026 which needs to be explained.

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

PLACE: BHOPAL
DATE: 13/08/2026

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049

BAHETI & CO.

CHARTERED ACCOUNTANTS

24,M.P. NAGAR ZONE II

BHOPAL 462011

2763141,4251535

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors of
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that

BAHETI & CO. Reg.No. 006287C BHOPAL CHARTERED ACCOUNTANTS we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement

For BAHETI & CO.
Chartered Accountants
(Firm Registration No 006287C)

Place: Bhopal
Date: 13/08/2026

BAHETI & CO. Reg.No. 006287C BHOPAL CHARTERED ACCOUNTANTS

(DEEPAK BAHETI)
Partner

Membership No: 075063

UDIN: 26075063UIFHTA2820

3B BLACKBIO DX LIMITED
REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023
CIN:L24211MP1972PLC001131

Statement of Consolidated Unaudited Financial Results For The Quarter Ended 30-06-2026

(Rs. In Lakhs)

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operations	3349.08	3543.41	2223.46	14191.81
II	Other income	614.30	1014.88	431.66	2555.81
III	**Total Income (I + II)**	**3963.38**	**4558.29**	**2655.12**	**16747.62**
IV	**Expenses:**				
	Cost of materials consumed	785.08	725.83	561.92	3573.85
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(29.94)	29.79	(5.97)	11.68
	Employee benefits expenses	854.74	935.84	176.54	2396.48
	Finance costs	10.25	10.41	1.05	23.71
	Depreciation and amortization expense	134.39	389.13	27.67	512.56
	Other expenses	886.91	1002.67	307.56	2532.37
	Total expenses (IV)	**2641.43**	**3093.67**	**1068.77**	**9050.65**
V	**Profit/(loss) before exceptional items and tax (III - IV)**	**1321.95**	**1464.62**	**1586.35**	**7696.97**
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	**Profit before tax (V - VI)**	**1321.95**	**1464.62**	**1586.35**	**7696.97**
VIII	Tax expense:				
	(1) Current tax	424.11	395.64	321.90	1615.49
	(2) Deferred tax	0.00	88.50	0.00	88.50
IX	**Profit (Loss) for the period (VII-VIII)**	**897.84**	**980.48**	**1264.45**	**5992.98**
	Profit or loss, attributable to owners of parent	953.19	955.51	1258.93	5858.59
	Total profit or loss, attributable to non-controlling interests	-55.35	24.97	5.52	134.39
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00
XI	**Total Comprehensive Income for the period (IX+X)**	**897.84**	**980.48**	**1264.45**	**5992.98**
	Profit or loss, attributable to owners of parent	953.19	955.51	1258.93	5858.59
	Total profit or loss, attributable to non-controlling interests	-55.35	24.97	5.52	134.39
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	32307.03	26243.65	26243.65	26243.65
XIV	**Earnings per equity share:**				
	(1) Basic	10.48	11.44	14.76	69.94
	(2) Diluted	10.48	11.44	14.76	69.94

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

PLACE: BHOPAL
DATE : 13/08/2026

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

NOTES ON CONSOLIDATED UN-AUDITED FINANCIAL RESULT FOR THE QUARTER ENDED 30th JUNE, 2026

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on August 13, 2026 after being reviewed by the Audit Committee.

2. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended;

3. The Company has two identified Reportable Business Segments namely Agrochemical and Molecular Diagnostic Kits (Health Care Sector)

4. The summarized figures for M/s 3B BLACKBIO DX LIMITED (FORMERLY, KILPEST INDIA LIMITED) (Both Agrochemicals and Diagnostic Division) as a standalone entity are:

PARTICULARS	QUARTER ENDED			YEAR ENDED
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	(unaudited)	(audited)	(unaudited)	(audited)
Total Income (Rs Lakhs)	2824.79	2593.34	2467.13	11143.70
Profit Before Tax (Rs Lakhs)	1835.32	1228.79	1567.94	6635.68
Profit After Tax (Rs Lakhs)	1411.21	744.65	1246.04	4931.69
Basic Earnings Per Share (Rs)	16.47	8.69	14.54	57.56

5. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures for the full financial year ended March 31, 2026 and unaudited figures for the nine months ended December 31 , 2025, being the date of the end of the third quarter of the financial year, which were subjected to limited review.

6. The Consolidated Financials include the Financials of Subsidiary Companies also.

7. All the figures of financials have been rounded off to nearest lakh in rupees.

8. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.

3B BlackBio Dx Limited
BHOPAL

9. The Results of the Company are available for investors at www.kilpest.com and www.bseindia.com

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter ended June 30, 2026 which needs to be explained

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

PLACE: BHOPAL
DATE: 13/08/2026

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049

BAHETI & CO.

CHARTERED ACCOUNTANTS
24,M.P. NAGAR ZONE II
BHOPAL 462011
2763141,4251535

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors of
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

We have reviewed the accompanying Statement of unaudited consolidated financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)('hereinafter referred to as 'the Holding Company') ,its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30th June 2026 ('the Statement') , being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BAHETI & CO. Reg.No. 006287C BHOPAL CHARTERED ACCOUNTANTS

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

i. 3B BlackBio Dx Limited (Formerly, Kilpest India Limited, Holding)

ii. TRUPCR Europe Limited (Subsidiary)

iii. Coris Holding, SRL, Belgium (Subsidiary)

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The unaudited interim financial results and other unaudited financial information of these subsidiaries have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For BAHETI & CO.
(FRN 006287C)
Chartered Accountants

Place: Bhopal
Date: 13/08/2026

BAHETI & CO. Reg.No. 006287C BHOPAL CHARTERED ACCOUNTANTS

(DEEPAK BAHETI)
Partner
Membership No.075063

UDIN 26075063EWSXMK5350

3B BLACKBIO DX LIMITED

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL–462 023

CIN:L24211MP1972PLC001131

CONSOLIDATED SEGMENTWISE REVENUE AND RESULTS

(Rs. In Lakhs)

		Quarter ended 30-06-2026 Unaudited	Quarter ended 31-03-2026 Audited	Quarter ended 30-06-2025 Unaudited	Year ended 31-03-2026 Audited
1	**Segment Revenue**				
	(a)Agrochemicals	143.34	337.99	227.40	1080.00
	(b) Diagnostic kits	3205.74	3205.42	1996.06	13111.81
	Total income from operations (net)	**3349.08**	**3543.41**	**2223.46**	**14191.81**
2	**Segment Results**				
	(a)Agrochemicals	0.03	10.94	(4.36)	14.12
	(b) Diagnostic kits	1332.16	1464.09	1591.77	7706.56
	Total Segment Profit before Interest and Tax	**1332.19**	**1475.03**	**1587.40**	**7720.68**
	Less : Interest Expense				
	(a)Agrochemicals	0.02	0.41	0.79	4.39
	(b) Diagnostic kits	10.22	10.00	0.26	19.32
	Profit before Tax	**1321.95**	**1464.62**	**1586.35**	**7696.97**
3	**Segment Assets**				
	(a)Agrochemicals	2786.22	2717.78	2888.30	2717.78
	(b) Diagnostic kits	35912.99	35081.75	26798.45	35081.75
	Total Segment Assets	**38699.21**	**37799.53**	**29686.75**	**37799.53**
4	**Segment Liabilities**				
	(a)Agrochemicals	253.39	201.73	400.86	201.73
	(b) Diagnostic kits	5281.95	4433.93	920.95	4433.93
	Total Segment Liabilities	**5535.34**	**4635.66**	**1321.81**	**4635.66**
	(a)Agrochemicals	2532.83	2516.05	2487.44	2516.05
	(b) Diagnostic kits	30631.04	30647.82	25877.50	30647.82
5	**Capital Employed**	**33163.87**	**33163.87**	**28364.94**	**33163.87**

FOR AND ON BEHALF OF THE BOARD

3B BlackBio Dx Limited BHOPAL

PLACE: BHOPAL
DATE : 13/08/2026

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049